{"id":"mtx-5-fu-sequential-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate (MTX) is a folate antagonist that inhibits dihydrofolate reductase, blocking thymidylate synthase and nucleotide synthesis. When followed by 5-fluorouracil (5-FU), which is converted to active metabolites that inhibit thymidylate synthase and incorporate into RNA/DNA, the sequential administration may enhance cytotoxic effects through modulation of 5-FU metabolism and increased cellular uptake of 5-FU metabolites.","oneSentence":"MTX + 5-FU sequential therapy combines methotrexate and 5-fluorouracil administered in sequence to inhibit nucleotide synthesis and DNA replication in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:20.206Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (phase 3 evaluation)"},{"name":"Colorectal cancer (potential indication)"}]},"trialDetails":[{"nctId":"NCT00149201","phase":"PHASE3","title":"A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis","status":"COMPLETED","sponsor":"Japan Clinical Oncology Group","startDate":"2002-11","conditions":"Gastric Cancer, Neoplasm Metastasis","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MTX + 5-FU sequential therapy","genericName":"MTX + 5-FU sequential therapy","companyName":"Japan Clinical Oncology Group","companyId":"japan-clinical-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MTX + 5-FU sequential therapy combines methotrexate and 5-fluorouracil administered in sequence to inhibit nucleotide synthesis and DNA replication in cancer cells. Used for Gastric cancer (phase 3 evaluation), Colorectal cancer (potential indication).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}